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Although acetylation is regarded as a common protein modification, a detailed proteome 
wide profile of this posttranslational modification may reveal important biological insight 
regarding differential acetylation of individual proteins. Here we optimised a novel peptide 
IEF fractionation method for use prior to LC-MS/MS analysis in order to obtain a more in 
depth coverage of N-terminally acetylated proteins from complex samples. Application of the 
method to the analysis of the serous ovarian cancer cell line OVCAR-5 identified 344 N-
terminally acetylated proteins, 12 of which are previously un-reported. The protein peptidyl-
prolyl cis-trans isomerase A (PPIA) was detected in both the N-terminally acetylated and un-
modified forms, and was further analysed by data independent acquisition in Carboplatin 
responsive parental OVCAR-5 cells and Carboplatin resistant OVCAR-5 cells. This revealed 
a higher ratio of un-acetylated to acetylated N-terminal PPIA in the parental compared to the 
Carboplatin resistant OVCAR-5 cells, and a 4.1-fold increase in PPIA abundance overall in  
the parental cells relative to Carboplatin-resistant OVCAR-5 cells (P = 0.015). In summary, 
the novel IEF peptide fractionation method presented here is robust, reproducible, and can be 
applied to the profiling of N-terminally acetylated proteins. All mass spectrometry data is 
available as a ProteomeXchange repository (PXD003547). 
 
KEYWORDS: N-terminal Acetylation, Ovarian cancer, carboplatin resistance, 
chemoresistance, peptidyl-prolyl cis-trans isomerase A, PPIA 
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Ovarian cancer is the seventh most common cancer and the eighth leading cause of cancer-
related deaths among women, responsible for approximately 250, 000 new cases and 150,000 
deaths each year worldwide 1. Due to delayed presentation and diagnosis, over 70% of 
women with ovarian cancer are diagnosed with stage III/IV disease. The standard treatment 
for stage III/IV diagnoses involves debulking surgery followed by combination chemotherapy 
with the drugs carboplatin and paclitaxel. Despite an 80% initial response rate, the majority 
of women exhibit disease relapse  and die from recurrent Carboplatin-resistant disease 2. It is 
therefore of  great importance to investigate mechanisms and markers that predict ovarian 
cancer resistance to standard chemotherapy regimens, in order to save patients from 
damaging, ineffective treatments, and determine if alternative regimens and novel drug 
combinations would be more beneficial.  
 
The chromosome centric human proteome project (C-HPP) aims for the characterisation of 
the ~20,300 proteins expressed by the protein-coding genome with respect to gene location 
on each chromosome, cellular distribution, and quantification 3, 4, 5. Moreover, the C-HPP 
also plans to map the major classes of post-translational modifications (PTM) for all of the 
identified proteins in disease related contexts 6. N(alpha)-terminal acetylation is one of the 
most common covalent protein modifications to occur in eukaryotes, with ~80% of soluble 
human proteins predicted to be N-terminally acetylated 7. N-terminal acetylation is an 
irreversible process that typically occurs during protein synthesis and involves the transfer of 
an acetyl group from acetyl coenzyme A to the α-amino group of a protein’s first amino acid, 
as catalysed by N-terminal acetyltransferases (NATs) 8. The functional changes induced by 
N-terminal acetylation can be highly variable but can be broadly categorized  into subcellular 
localization, protein interactions and complex formation, protein folding, and perhaps the 
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most well-known, protein degradation with regard to the N-end rule 9, 10, 11. The N-end rule 
pathway targets proteins for ubiquitin-mediated degradation based on their N-terminal 
residue and the PTM status of this residue. These degradation signals are known as N-
degrons.   
 
Initially N-terminal acetylation was shown to block ATP-dependent ubiquitin-mediated 
degradation 12, however it has also been shown to promote sequence specific protein 
degradation  13. In eukaryotes there are two N-end rule pathways that form part of the 
ubiquitin system that target the majority of cellular proteins for degradation; the Ac/N-end 
and the Arg/N-end rule pathways. In the Ac/N-end rule pathway, proteins containing N-
terminally acetylated residues are targeted for degradation. Conversely, the Arg/N-end rule 
pathway targets specific un-acetylated N-terminal residues (Arg, Phe, Lys, Leu, His, Tyr, 
Trp, and Ile) and N-terminal Asn and Gln which have been deaminated and then Arginylated 
14. Un-acetylated N-terminal Met followed by a hydrophobic residue are also targeted for 
degradation by the Arg/N-end rule pathway 15. Protein N-terminal acetylation is thought to be 
relevant to cancer development with NATs acting as tumour suppressors in healthy tissues 
and oncoproteins in cancerous cells 16. 
 
The aims of this study were to characterise the N-terminal acetylation profile of the ovarian 
cancer cell line OVCAR-5 in order to identify novel acetylation sites and help determine if 
the occurrence of N-terminal acetylation differs in chemoresistant cells and therefore can be 
used as putative markers for chemotherapeutic resistance in ovarian cancer. In order to 
comprehensively profile the N-terminal acetylation sites and develop spectral libraries, a 
novel IEF Sephadex flatbed gel method for peptide fractionation of up to 10 mg was 
developed and applied prior to nano-LC-ESI-MS/MS. The novel method was first applied to 
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trypsin digested mouse brain lysates to show the technique is capable of separating and 
improving the coverage of highly complex peptide mixtures. Following this the method was 
then applied to OVCAR-5 cell lysates, enabling the detection of 344 N-terminally acetylated 
proteins, 12 of which are previously un-reported. This stands in contrast to the 189 N-
terminal acetylation sites detected in the unfractionated OVCAR-5 sample.  
 
To determine if variable N-terminal acetylation may play a role in the development of 
chemoresistance, the results from the IEF fractionation were searched for N-terminally 
acetylated proteins present in both the modified and un-modified forms that could be 
analysed further in non-resistant (parental) and carboplatin resistant (CBPR) OVCAR-5 cells.  
The protein peptidyl-prolyl cis-trans isomerase A (PPIA), also known as Cyclophilin A, was 
identified and selected for further analysis given the protein’s potential involvement in 
chemoresistance 17 and given the protein was detected in both the N-terminally acetylated and 
un-acetylated forms. PPIA was quantified using data independent acquisition methods in the 
parental and CBPR OVCAR-5 cells. This revealed a higher ratio of un-acetylated to 
acetylated N-terminal PPIA in the parental compared to the CBPR cells, and a 4.1-fold 
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Materials and Methods  
Preparation of tryptic peptides from mouse brain samples 
Freshly dissected P30 mouse brain was lysed at room temperature under denaturing 
conditions in 10mL of lysis buffer (8 M urea (Merck, Darmstadt, Germany), 20 mM HEPES 
(ICN Biochemicals, Ohio, USA), pH 8, complete protease inhibitors (Roche, Basel, 
Switzerland), 10mM NaF (Sigma-Aldrich, St. Louis, USA), 1mM Na3VO4 (Sigma-Aldrich), 
1 mM beta-glycerophosphate (Sigma-Aldrich), 2.5 mM sodium pyrophosphate (Sigma-
Aldrich)) with 6 titrations through an 18G needle (Becton Dickinson, Franklin Lakes, USA), 
followed by 6 titrations through a 21G needle (Becton Dickinson), followed by 3 x 15 second 
pulses with a 300W sonicator (Branson, Danbury, USA) at 50% amplitude. Lysates were 
centrifuged at 20,000 x g for 15 minutes at 20°C to remove insoluble material and protein 
concentrations were estimated using an EZQ protein assay (Life Technologies, Carlsbad, 
USA). The samples were reduced with 5 mM DTT (Roche) for 45 min at room temperature 
and alkylated with 10 mM iodoacetamide (IAA) (GE Healthcare, Little Chalfont, UK)) for 30 
minutes at room temperature in the dark. Lysates were then diluted to 2 M urea with 20 mM 
HEPES, pH 8, and digested overnight at 25°C with trypsin-TPCK (Worthington 
Biochemicals, Lakewood, USA) at an enzyme to substrate ratio of 1:50. Following digestion, 
samples were acidified with formic acid (FA) (Sigma-Aldrich) and subsequently desalted 
using 500 mg C18 Sep-Pak SPE cartridges (Waters, Milford, USA). C18 cartridges were 
conditioned with 5 mL of 100% Acetonitrile (ACN) (Merck), followed by 5 mL of 50% (v/v) 
ACN, 0.1% FA, and finally 20 mL of 0.1% trifluoroacetic acid (TFA) (Sigma-Aldrich). 
Sample was loaded onto the conditioned C18 cartridge, washed with 15 mL of 0.1% TFA, 
and eluted with 6 mL of 50% ACN, 0.1% FA. Desalted samples were dried to completeness 
overnight in an Alpha 1-2 freeze drier (Martin Christ, Osterode am Harz, Germany). The 
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peptides were then resuspended in 10% ACN to a concentration of 10mg/mL as estimated by 
the initial protein amount before digestion. 
 
Peptide fractionation by IEF Sephadex gel flatbed electrophoresis  
335 mg of Sephadex G-100 SF (GE Healthcare) was mixed with 3 mL 10% (v/v) Acetonitrile 
(ACN) (Merck) and rehydrated for 72 hours at room temperature. Subsequently, the required 
volume of mouse brain tryptic digest for 1 mg or 10 mg peptides (0.1 mL or 1 mL, 
respectively), 180 µL Pharmalyte 3-10 (GE Healthcare) and 50 µL pI-marker mixture (14) 
were added. Thereafter, 10% (v/v) ACN (Merck) was added to a total volume of 4.5 mL and 
mixed carefully, to not introduce air-bubbles, with a 5 mL pipette (Eppendorf, Hamburg, 
Germany). The mixture was pipetted into a lane (Dimensions: (10 x 1) cm2) in a HD-PE tray, 
a layer of six Whatman 3MM Chr paper (GE Healthcare) was wetted in the respective 
cathode (100 mM NaOH (Merck)) or anode solution (100 mM H2SO4 (Merck)) and applied 
to the ends of the lane. The mixture was then distributed homogenously in the lane by short, 
rapid movements of the HD-PE tray. IEF was conducted using a Multiphor II apparatus (GE 
Healthcare) at 4 °C, with the voltage limited to 1500 V and current limited to 0.1 mA/ cm2 
lane area until 1,000 Vhrs (1mg peptides) or 1,300 Vhrs (10 mg peptides) were reached. 
Following separation, 20 fractions were collected into 1.5 mL 0.22 µm cellulose acetate spin-
filter-tubes (Corning, New York, USA) using a spatula. Sephadex fractions were eluted with 
3 x 200 µL 10% (v/v) ACN using a bench-top centrifuge. Elution of peptides was deemed 
complete at this point as no pI-marker was left visible in the Sephadex gel. In the case of the 
1 mg of fractionated mouse brain peptides, the eluate was concentrated using a vacuum 
centrifuge until approximately 100 µL solution was left and diluted 1:10 in 2% (v/v) ACN, 
0.1% (v/v) formic acid in 97.9% water (FA2). For the 10 mg of the fractionated mouse brain 
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peptides, the vacuum concentration step was omitted and the eluate was directly diluted 1:10 
in FA2. 
 
OVCAR-5 sample preparation and IEF fractionation 
For fractionation by IEF the OVCAR-5 cells were lysed using a Precellys 24 bead beater. 
Briefly, the cells were placed in Precellys bead beating tubes (Bertin Technologies, 
Montigny-le-Bretonneux, France) in 1% (w/v) SDS (GE Healthcare) and homogenised using 
a Precellys 24 (Bertin Technologies) at 6,300 revolutions per minute for 3 x 1 minute cycles. 
The samples were centrifuged at 20,000 x g for 30 minutes, the supernatant was recovered 
and DNA was subsequently sheared using a Bioruptor (Diagenode, Seraing, Belgium) set to 
“high” output for 6 x 30 second cycles with one minute breaks between each cycle. 
Sonication was carried out in ice-cold water. Protein concentration was quantified using an 
EZQ protein assay (Life Technologies). Protein extracts were digested with a modified FASP 
method as previously described by Wisniewski e.t al.(2009) 18. Briefly, samples were made 
up to a volume of 200 µL with 7M urea (Merck), 100mM ammonium bicarbonate (U-
AmBic) (Merck) and reduced by adding a final volume of DTT to 50 mM (Roche) followed 
with incubation at 20°C for 1 hour. Vivacon ultrafiltration spin columns (Sartorius Vivacon 
500, 10,000 MWCO HY) were pre-rinsed at 14,000 x g for 10 minutes with 100 µL U-
AmBic to remove traces of glycerine. Samples were loaded into the spin columns and 
centrifuged at 14,000 x g for 10 minutes. 100 µL of 55 mM IAA (GE Healthcare) in U-
AmBic was added to the spin columns and incubated in the dark for 20 minutes at 20°C. 
Samples were centrifuged at 14,000 x g for 10 minutes and washed with 100 µL of U-AmBic 
twice, followed by one wash with 100 µL of 50 mM U-AmBic. Samples were digested 
overnight at 37°C with trypsin gold (Promega, Madison, WI, USA) at an enzyme to substrate 
ratio of 1:50 in 100 µL of 5 mM U-AmBic. 1 mg tryptic peptides from the OVCAR-5 cells 
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was desalted, dried to completeness, re-suspended in 100 µl 10% (v/v) ACN (Merck), and 
IEF was carried out as described above until 1,000 Vh were reached. Once separated the 
sample was collected into 20 fractions and prepared for nano-LC-ESI-MS/MS as described 
above.  
 
Generation of carboplatin resistant OVCAR-5 cells 
The human serous ovarian cancer cell line, OVCAR-5 was obtained from Dr. Thomas 
Hamilton (Fox Chase Cancer Centre, Philadelphia, PA) and cultured under conditions as 
previously described 19. OVCAR-5 carboplatin resistant cells were derived from the parental 
OVCAR-5 cells by continuous exposure to carboplatin (Hospira Australia Pty Ltd). OVCAR-
5 cells were cultured in T-75 flasks and treated with 25µM of carboplatin for 24 hours 
followed by a recovery phase (cells in normal growth media) for 72 hours. The 25µM dose of 
carboplatin was chosen because the inhibitory concentration (IC50) carboplatin results in the 
OVCAR-5 cell senescence and delayed cell growth. The OVCAR-5 cells exposure to 
carboplatin and recovery phase cycle was repeated for 8 cycles and development period was 
performed within 8-10 weeks. Cell survival was calculated using a MTT assay, as per the 
manufacturer’s instructions (Sigma-Aldrich), as previously described 19. The (IC50) of 
carboplatin was calculated from three independent experiments performed in triplicate using 
exponential regression curve fitting. We observed a 2.3 fold increase in IC50 of the OVCAR-5 
CBPR cells (IC50 = 232 µM) compared to the parental OVCAR-5 cells (IC50 = 98 µM). For 
data independent acquisition mass spectrometry 300 ng the parental OVCAR-5 and OVCAR-
5 CBPR cell lysate was analysed. These cells were prepared as described in the previous 
section, without the use of the IEF fraction step. 
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Nano -LC-ESI-MS/MS    
Nano-LC-ESI-MS/MS was performed using an Ultimate 3000 RSLC system (Thermo-Fisher 
Scientific, Waltham, USA) coupled to an Impact HD™ QTOF mass spectrometer (Bruker 
Daltonics, Bremen, Germany) via an Advance CaptiveSpray source (Bruker Daltonics). 
Approximately 1 µg from each of the 20 mouse brain and OVCAR-5 fractions, and 1 µg 
from the un-fractionated mouse brain and OVCAR-5 digests were analysed. Peptide samples 
were pre-concentrated onto a C18 trapping column (Acclaim PepMap100 C18 75 µm × 20 
mm, Thermo-Fisher Scientific) at a flow rate of 5 µL/ min in 2% (v/v) ACN 0.1% (v/v) TFA 
for 10 minutes. For all IEF fractionated samples peptide separation was performed using a 75 
µm ID C18 column (Acclaim PepMap100 C18 75 µm × 50 cm, Thermo-Fisher Scientific) at 
a flow rate of 0.2 µL/ minutes using a linear gradient from 5 to 45% B (A: 5% (v/v) ACN 
0.1% (v/v) FA, B: 80% (v/v) ACN 0.1% (v/v) FA) over 130 minutes, followed by a 20 
minute wash with 90% B, and a 20 minute equilibration with 5% A. MS scans were acquired 
in the mass range of 300 to 2,200 m/z in a data-dependent fashion using Bruker’s Shotgun 
Instant Expertise™ method. This method uses IDAS (intensity dependent acquisition speed) 
to adapt the speed of acquisition depending on the intensity of precursor ions (fixed cycle 
time), and RT2 (RealTime Re-Think) to exclude previously selected precursor ions from 
undergoing re-fragmentation unless the chromatographic peak intensity of the ion has 
increased by a factor of 5. Singly charged precursor ions were excluded from acquisition. 
Collision energy ranged from 23% to 65% as determined by the m/z of the precursor ion. 
 
Nano-LC-ESI-MS/MS data analysis  
All spectra collected using data dependent acquisition (DDA) were analysed using the 
MaxQuant software (version 1.5.2.8) with the Andromeda search engine 20 against the 
UniProt human database (downloaded on the 13th of October 2015, containing 20,204 entries) 
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for the OVCAR-5 cell line and against the UniProt mouse database (downloaded on the 13th 
of October 2015, containing 16,785 entries) for the mouse brain lysates. For the OVCAR-5 
data, all novel N-terminal acetylation and methionine cleavage site identifications were also 
checked against the UniProt human database containing all isoforms to ensure matching was 
genuine and not caused by protein isoforms. The standard Bruker QTOF settings in 
MaxQuant were used with a mass error tolerance of 40 ppm. The variable modifications of 
oxidation of methionine and N-terminal acetylation and the fixed modification of 
carbamidomethyl of cysteines were specified, with the digestion enzyme specified as trypsin. 
The protein false discovery rate (FDR) and peptide spectrum match FDRs were both set to 
1% using a target decoy approach, with a minimum peptide length of 7 amino acids 20. Only 
unique and razor peptides were used when reporting protein identifications. For the status of 
N-acetylation, the neXtProt 21 (02-2016) and PRIDE databases were consulted. 
 
Further data analysis was carried out using R (Version 3.0.1, The R Foundation for Statistical 
Computing) 22 and additionally the ggplot2 v1.01 23 package. The mass spectrometry 
proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE 24 
partner repository with the dataset identifier PXD003547. 
 
Quantification of PPIA by DIA  
Nano-LC was performed as described above on 300 ng of the CBPR and un-treated parental 
OVCAR-5 cells using an Ultimate 3000 RSLC system coupled to an Impact HD™ QTOF 
mass spectrometer set to acquire data using Bruker’s Middle Band CID™ method. This data 
independent acquisition (DIA) method scans a mass range of m/z 375 to 1,206 in 26 Da 
increments and CID is performed with increasing collision energies of 20 to 36. The acquired 
data was analysed using Skyline (Version 3.1.0.7382) 25 against a spectral library generated 
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from the results of the OVCAR-5 IEF fractionation experiment. Analysis of PPIA abundance 
in the parental compared to CBPR OVCAR-5 cells (n=2) was carried out using the following 
spectral library peptides for quantification; V[+42]NPTVFFDIAVDGEPLGR (2+), 
VNPTVFFDIAVDGEPLGR (2+), VSFELFADK (+3), SIYGEKFEDENFILK (3+), 
FEDENFILK (+2), KITIADC[+57]GQLE (+2), and ITIADC[+57]GQLE (+2). The Skyline 
peptide and transition settings were as follows: trypsin was specified as the cleavage enzyme 
with a maximum of 1 missed cleavage, precursor charge states 2 and 3, ion charges 1 and 2, 
ion types y and b from ion 2 to ion 6, an ion match tolerance 0.1 m/z, a MS/MS filtering DIA 
isolation scheme from m/z 375 to 1,206 (26 Da windows), retention time window of 5 
minutes, and a resolution of 10,000.  For analysis of the un-modified vs acetylated N-terminal 
peptide of PPIA in the parental compared to CBPR OVCAR-5 cells (n=3), the % of the un-
acetylated VNPTVFFDIAVDGEPLGR relative to the acetylated 
V[+42]NPTVFFDIAVDGEPLGR peptide was calculated. To calculate the relative 
abundance of PPIA overall, the area intensities of the detected peptides was summed.  For all 
results the standard error of the mean and P values using un-paired t-tests were calculated 
using GraphPad Prism 6 v008.  
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Validation of IEF Sephadex gel flatbed electrophoresis method using mouse brain 
Fractionation of the mouse brain sample prior to nano-LC-ESI-MS/MS analysis significantly 
increased the total number of peptide and protein identifications obtained. The number of 
unique protein identifications with an FDR of 1% increased from 1,984 in the unfractionated 
sample (1 µg of digest analysed) to 3,716 and 3,546 in the 1 mg and 10 mg IEF fractionated 
mouse brain samples, respectively (both 1 µg of digest analysed per fraction). The peptide 
fractionation was deemed satisfactory, as 70% of the peptides were detected in 2 fractions or 
less from a total of 20 fractions (Figure 1A). Increasing the peptide load from 1 mg to 10 mg 
did not alter the quality of peptide separation, as in the case of the 10 mg load, 75% of 
peptides were identified in 2 fractions or less (Figure 1B). A median of 4 additional peptides 
were identified per protein in the 1 mg of fractionated sample as compared with the 
unfractionated sample, with additional peptides identified for 86% of the proteins overall 
(Figure 1C). For the 10 mg IEF fractionated sample the median increase in the number of 
peptides identified per protein was 3, with additional peptides identified for 78% of proteins 
(Figure 1D). The mean additional sequence coverage obtained by the IEF fractionation was 
15% for the 1 mg sample and 10% for the 10 mg sample (Figure 1E, F). 
 
N-terminal acetylation analysis of the IEF fractionated ovarian cancer cell line OVCAR-5 
Following validation of the peptide IEF fractionation, the method was applied to the ovarian 
cancer cell line OVCAR-5. In total 4,305 unique proteins were identified from the OVCAR-5 
cells (protein FDR of 1%) of which 2,067 were exclusively detected in the 1 mg IEF 
fractionated sample (Supporting Table 1a), as compared to 2,282 proteins detected  in the 1 
µg of unfractionated sample (44 exclusively identified) (Supporting Table 1b). Between the 
IEF fractionated and un-fractionated analyses there was an overlap of 2,238 proteins 
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identified in both experiments. The total number of unique peptides identified in the IEF 
fractionated sample was 17,773 (peptide FDR of 1%) as compared to 7094 identifications in 
the unfractionated OVCAR-5 cells (peptide FDR of 1%).  Additional peptides (median: 2) 
were identified for 90% of proteins and a mean additional protein sequence coverage of 9.1% 
was gained in the IEF fractionated sample as compared to the un-fractionated sample 
(Supporting Figure 1). The chromosomal locations of the corresponding genes for all of the 
identified proteins (IEF fractionated and unfractionated) are provided in Supporting Figure 2. 
All of the detected proteins had an evidence level of PE1 except for androglobin (Q8NX0), 
which had an evidence level of PE2. However, only one peptide from this protein was 
identified and hence it does not meet the strcit HPP criteria for the detection of low evidence 
level proteins, where a minimum of 2 unique peptides with a length of ≥9 amino acids is 
required.  
 
The total number of identified N-termini peptides was 446 (acetylated and un-acetylated, 
Supporting Table 2a and 2b), of which 401 were detected in the IEF fractionation OVCAR-5 
samples, and 215 were detected in the unfractionated OVCAR-5 sample. The overall number 
of identified N-terminal acetylation sites was 382 (85.6% of all N-termini detected), with an 
overlap between the IEF and un-fractionated samples of 170. In the IEF fractionated 
OVCAR-5 sample a total of 344 N-terminal acetylation sites were detected, 12 of which are 
previously un-reported in both the neXtProt and PRIDE databases. Annotated spectra 
exported from MaxQuant for these peptides are provided in Supporting Figure 3. This stands 
in contrast to 189 N-terminal acetylation sites identified in the unfractionated OVCAR-5 
sample, 4 of which were novel, however 3 of these were also identified in the fractionated 
sample. The data was further analysed for initiator methionine cleavage. Forty-four proteins 
were detected to have undergone initiator methionine cleavage, none of which have been 
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previously reported. The acetylation status, initiator methionine presence or cleavage, and 
sample information for the detected novel N-terminal peptides is summarised in Table 1. 
 
Of the detected N-terminally acetylated amino acid residues 51.6% were Ala, 23.3% were 
Met, 18.8% were Ser, 4.2% were Thr, 0.8% were Val, 0.5% were Cys, with Asp, Glu, and 
Gly each contributing 0.3%. Details for the detected N-terminally acetylated amino acid 
residues, un-modified N-terminal amino acid residues, and the following amino acid residues 
for all detected N-terminal peptides are provided in Supporting Table 3.  
 
The N-terminus of 7 proteins from the IEF fractioned sample were detected with the initiator 
methionine present and also in the initiator methionine cleaved form (proteins Q96HQ2, 
Q14974, P62937, P56385, P49189, P46782, P31939). Only one of these proteins was 
detected in both forms in the unfractionated OVCAR-5 sample. However, both N-terminal 
forms (with and without initiator methionine) could be detected for 6 of the 7 proteins in 300 
ng of the unfractionated OVCAR-5 sample when analysed by DIA using a spectral library 
generated from the IEF fractionated sample (Supporting Figure 4).   
 
Quantification of PPIA in parental and CBPR OVCAR-5 cells 
The IEF fractionated OVCAR-5 results were searched for N-terminally acetylated proteins 
present in both the modified and un-modified forms, which highlighted the protein peptidyl-
prolyl cis-trans isomerase A (PPIA), also known as Cyclophilin A. In order to determine if 
the N-terminal acetylation of PPIA is altered in chemoresistant cells, CBPR and parental 
OVCAR-5 cells were analysed by DIA nano-LC-ESI-MS/MS. The level of N-terminal 
acetylation between the acetylated and un-modified N-terminal peptide of PPIA 
(VNPTVFFDIAVDGEPLGR) was analysed in the parental and CBPR OVCAR-5 cells (n=3) 
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revealing 24.4% ±3.3% un-acetylated to acetylated peptide in the parental OVCAR-5 cells 
compared to 9.4% ±4.2% in the CBPR OVCAR-5 cells, P=0.025 (Figure 2.A). This indicates 
a higher proportion un-acetylated N-terminal peptide in the parental cells as compared to the 
CBPR cells. Overall quantification of PPIA found the protein to be significantly increased in 
the parental OVCAR-5 cells as compared to the CBPR OVCAR-5 cells (n=2) 4.1 fold, P = 
0.015 (Figure 2.C).  
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In-line with the C-HPP, one aim of this study was to map novel N-terminal acetylation sites 
from proteins extracted from the ovarian cancer cell line OVCAR-5.  In order to 
comprehensively characterise the human proteome, sample fractionation and analysis 
methods that allow for the detection of previously uncharacterised proteins and modifications 
are required. Isoelectric focusing of proteins using Sephadex as a matrix has been previously 
described by Radola et al. 26 and Görg et al. 27: the protocol described here has been adjusted 
to enable the separation of peptides while being directly compatible with downstream 
analysis by nano-LC-ESI-MS/MS and allowed for the detection of 12 previously un-reported 
N-terminal protein acetylation sites. 
 
Several protein and peptide pre-fractionation methods are available and are routinely used 
prior to MS analysis, most utilising strong cation exchange, strong anion exchange or some 
form of IEF. These methods have been shown to work with peptide amounts of up to one 
milligram 28, however the best resolution was achieved when peptide loads in the high 
microgram range were used 29, 30. The variant of isoelectric focusing presented here allows for 
separation of peptide amounts of up to at least 10 mg while retaining the resolving power 
observed at lower loads. The high loading capacity of the technique is ideal for samples 
available in large quantities that also exhibit a high dynamic range of protein abundance, as it 
increases the chances of detecting very low abundance peptides, in particular peptides 
exhibiting PTMs. Further advantages of the method are that it is cost-effective, flexible in the 
number of fractions sampled, the separation distance is freely adjustable and the user has the 
ability to parallelize fractionations (e.g. our custom made HD-PE tray allows for 
simultaneous fractionation of up to 7 samples). Additionally, the method is easy to implement 
and requires only an electrophoretic chamber with cooling plate. The time required for the 
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fractionation is relatively short and can usually be finished within 6 hours, inclusive set-up 
and sampling time (excluding 72 h passive rehydration time required for the Sephadex gel). 
Therefore, this method is an interesting candidate for laboratories that want to establish their 
own, more comprehensive spectral libraries for data-independent mass spectrometry 
experiments (e.g. SWATH or middle-band CID), without the acquisition of additional, highly 
specialized and expensive equipment. 
 
Overall a total of 4,305 unique proteins were identified in the IEF fractionated OVCAR-5 
sample as compared to 2,282 proteins in the unfractionated sample (protein FDR of 1%). 
From these results 379 proteins were detected as being N-terminally acetylated and 63 
proteins were detected as being un-modified at the N-terminus.  An interesting study by 
Lange et al. 31 profiled the N-terminal acetylation status of the naturally degraded proteome 
of human erythrocyte cells using the TAILS method 32. The majority of the N-termini 
detected in the study mapped to positions within the protein sequence, revealing proteolytic 
processing in 64% of cases with a large amount of N-terminal acetylation. Lange et al. then 
analysed the frequency of the specific N-terminally acetylated amino acids observed and 
were able to define a stabilising N-end rule for N-termini generated by post translational 
proteolytic cleavage. The results showed Leu, Ile, and Phe to have the highest levels of 
acetylation, followed by Ala and Val, with little Ser and Thr N-terminal acetylation. These 
findings are in contrast to the data presented in this study, which found high levels of Ala, 
Met, and Ser N-terminal acetylation, a low level of Thr and Val  N-terminal acetylation, and 
no Leu, Ile, and Phe N-terminal acetylation. The differences observed could be a reflection of 
N-terminal processing of original or intact protein N-termini as compared to Lange et al. 
which investigated new N-termini produced as a result of proteolytic cleavage. 
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The 379 proteins detected as being N-terminally acetylated in the IEF fractionated and 
unfractionated OVCAR-5 cells were mined for N-terminally acetylated proteins present in 
both the modified and un-modified forms. Such proteins were of interest for analysis in 
responsive parental and carboplatin resistant (CBPR) OVCAR-5 cells with the aim of 
determining whether variable N-terminal acetylation may be involved in, or altered during, 
the development of chemoresistance. The protein peptidyl-prolyl cis-trans isomerase A 
(PPIA), also known as Cyclophilin A or Cyclosporin A-binding protein, was detected using 
these parameters and selected for further analysis given the protein’s potential involvement in 
chemoresistance 17. When compared to the total amount of detected PPIA N-terminus, the 
relative abundance of the un-modified to acetylated form was 24.4% ±3.3% in the un-treated 
parental cells and 9.4% ±2.7% in the CBPR cells (P=0.025). This result suggests a trend 
towards more un-acetylated PPIA N-terminus in the cells that had not been treated with 
Carboplatin.  Given the first amino acid of the PPIA N-terminus is Val (after cleavage of the 
initiator Met) using the Ac/N-end rule pathway, the presence of more un-acetylated N-
terminus would suggest less degradation. Upon further investigation the overall relative 
abundance of PPIA was found to be significantly increased in the parental OVCAR-5 cells 
compared to the treated carboplatin resistant cells 4.1 fold, P=0.015. 
 
PPIA is a peptidyl-prolyl cis-trans isomerase (PPIase), a family of proteins with molecular 
chaperone functions that also catalyse a rate-limiting protein folding process. PPIA falls 
directly under the transcriptional control of p53 and HIF1 alpha and has been implicated in a 
number of cancers with expression levels correlating to malignant transformation 33, 34. 
Expression of PPIA is essential for the conformational maintenance of oncogenes, signaling 
proteins involved in cell proliferation, anti-apoptotic functions, transcription factors, and cell 
motility regulatory proteins 17. The immunosuppressant drug cyclosporine A is known to 
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inhibit PPIA, a drug that has the capacity to sensitise Cisplatin and Carboplatin resistant 
ovarian tumours 35. Given PPIA can protect cells against oxidative-stress induced apoptosis 
36, 37 it has been hypothesised that cyclosporine A may act to reduce chemoresistance partially 
via the inhibition of PPIA. A study analysing gene expression prior to and following 
chemotherapy in ovarian tumour tissues found PPIA expression to be increased 2 fold 
following treatment, however the result was not significant 38. A study analysing 
chemoresistance to the drug 3-bis (2-chloroethyl)-1-nitrosourea in malignant rat glioma cells 
found PPIA to be decreased in the drug resistant compared with responsive cells at the 
protein level 39, confounding the results observed here. Interestingly a study analysing 
paclitaxel chemoresistance in the ovarian cancer cell line SKOV3 found another PPIase, 
FKBP5, to be transiently up-regulated 100 fold at the mRNA level whilst chemoresistance 
was being established in the cells 40. Long term expression of FKBP5 however, was 
decreased in the resistant cells compared to the responsive cells.   
 
Conclusion 
Further validation of the overall expression and variable N-terminal acetylation of PPIA in 
responsive versus chemoresistant ovarian cancer cell lines is required to determine if PPIA is 
involved in, or altered by, Carboplatin treatment. Ideally the expression and N-terminal 
acetylation status of PPIA would be analysed in patient samples prior to and following 
chemotherapy. Such an analysis is hampered only by the difficulty in collecting tissue 
samples following treatment, as patients rarely receive further surgery at this point.  In 
summary the novel IEF peptide fractionation method presented here is a robust, reproducible, 
and a cost effective way of increasing the sequence coverage of protein digests and post-
translationally modified peptides analysed by nano-LC-ESI-MS/MS. Although we did not 
conduct a direct comparison of our method to targeted N-terminomic methods like 
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COFRADIC 41 or TAILS 32, the data presented implies that our method is capable to cover N-
terminally modified peptides in at least a complementary fashion, as indicated by their entries 
into the neXtProt database Therefore our method is of particular use when establishing 
spectral libraries for DIA analysis. 
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Figure 1. Verification of the IEF Sephadex gel flatbed electrophoresis method for peptides 
using mouse brain. The number of fractions a specific peptide was identified in (1mg mouse 
brain IEF (A) and 10 mg mouse brain IEF(B)). The number of additional peptides identified 
per protein in the 1 mg of mouse brain IEF fractionated sample as compared to the 
unfractionated sample. The median number of additionally identified peptides was 4. D) The 
number of additional peptides identified per protein in the 10 mg of mouse brain IEF 
fractionated sample as compared to the unfractionated sample. The median number of 
additionally identified peptides was 3. E) The additional protein sequence coverage in the 1 
mg of mouse brain IEF fractionated sample as compared to the unfractionated sample, a 
mean increase of 14.86%. F) The additional protein sequence coverage in the 10 mg of 
mouse brain IEF fractionated sample as compared to the unfractionated sample, a mean 
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Figure 2. Relative abundance of PPIA in un-treated parental OVCAR-5 cells compared to 
CBPR OVCAR-5 cells as quantified by DIA nano-LC-MS/MS. A) The percentage of Un-
Acetylated to Acetylated VNPTVFFDIAVDGEPLGR in the parental (24.4% ±3.3%) and 
CBPR (9.4% ±2.7%) OVCAR-5 cells (n=3), P=0.025. B) Peptide spectra of 
VNPTVFFDIAVDGEPLGR and V[+42]NPTVFFDIAVDGEPLGR used as library 
references for the relative quantification analysis performed in the software Skyline. C) 
Relative abundance of PPIA in the parental (9.1x107 ±1.2 x107) and CBPR (2.2x107 ±3.6 
x106) OVCAR-5 cells (n=2) as quantified from the peptides VSFELFADK (+3), 
SIYGEKFEDENFILK (3+), FEDENFILK (+2), KITIADC[+57]GQLE (+2), and 
ITIADC[+57]GQLE (+2). PPIA was increased in the parental cells 4.1 fold as compared to 
the CBPR cells, P=0.015. D) Spectra for the reference library peptides used for the relative 
quantification of PPIA.  
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5 at Position 1 - - - x 3 - x
26 at Position 2 x - x x 9 x x
1 at Position 2 x x - x 0 - x
4 - x - x - 0 x -
12 - x - x - 1 x -
48 - - - 44 32 13 10 12
47 - - - 44 31 13 10 12
42 - - - 40 27 12 10 11
6 - - - 4 5 1 0 1
1 - - - 0 1 0 0 0
















p Total number of N-terminal peptides identified in IEF fractionated and unfractionated OVCAR-5 cell line
N-terminus has not been described neither in neXtProt nor in PRIDE
N-acetylation has not been described neither in neXtProt nor in PRIDE
Number of identified peptides not described in neither neXtProt nor PRIDE
Total number of N-terminal peptides identified exclusively in IEF fractionated OVCAR-5 cell line
Total number of N-terminal peptides identified in unfractionated OVCAR-5 cell line
Total number of N-terminal peptides identified exclusively in IEF fractionated OVCAR-5 cell line
N-acetylation has not been described in the literature before according to neXtProt
Total number of N-terminal peptides identified
Total number of N-terminal peptides identified in IEF fractionated OVCAR-5 cell line
Initiator methionine removed (x) or alternation according to neXtProt
Position of N-acetylation according to neXtProt
N-terminus has not been described in the literature before according to neXtProt
Number of identified peptides not described in neXtProt
Position of N-acetylation of identified peptide
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Supporting Information  
Table S-1a. OVCAR-5 IEF fractionated nano-LC-ESI-MS/MS protein identification results. 
Table S-1b. OVCAR-5 nano-LC-ESI-MS/MS protein identification results (unfractionated). 
Table S-2a. N-terminal site identification results from the IEF fractionated and 
unfractionated OVCAR-5 cells.  
Table S-2b. Novel N-terminal site identification results from the IEF fractionated and 
unfractionated OVCAR-5 cells 
Table S-3. Number, percentage, and type of the detected acetylated and un-modified N-
terminal amino acid residues.  Number, percentage, and type of the amino acid following the 
N-terminal amino acid residue. 
 
Figure S-1. OVCAR-5 IEF peptide fractionation results. 
Figure S-2. The chromosomal locations of the corresponding genes for all of the OVCAR-5 
identified proteins.  
Figure S-3. Annotated spectra for all peptides identified with novel N-terminal acetylation or 
methionine cleavage sites.   
Figure S-4. Detection of N-terminal peptides with and without initiator methionine in the 
unfractionated OVCAR-5 cells by DIA. 
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CBPR, carboplatin resistance 
COFRADIC, combined fractional diagonal chromatography 
DIA, data independent acquisition  
PPIA, peptidyl-prolyl cis-trans isomerase A  
TAILS, terminal amine isotopic labeling of substrates 
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